Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iparomlimab - Qilu pharmaceutical

Next Previous
Drug Profile

Iparomlimab - Qilu pharmaceutical

Alternative Names: PD-1 monoclonal antibody; PSB-103 - Qilu Pharmaceutical; QL-1604

Latest Information Update: 01 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Qilu Pharmaceutical
  • Developer Qilu Pharmaceutical; Tianjin Medical University Cancer Institute and Hospital
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Solid tumours
  • Phase II/III Cervical cancer
  • Phase II Oesophageal cancer
  • Phase I/II Liver cancer

Most Recent Events

  • 01 Mar 2025 Phase-II clinical trials in Oesophageal cancer (Late-stage disease, Inoperable/Unresectable, In the elderly) in China (IV) (NCT07038629)
  • 23 Jan 2025 Efficacy and adverse events data from phase Ib/II DUBHE-H-106 trial in Liver cancer presented at the Gastrointestinal Cancers Symposium (ASCO-GI-2025)
  • 06 Jun 2024 Adverse events and efficacy data from a phase II trial in Solid tumours released by Qilu Pharmaceutical

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top